Ben Izar's lab is a pioneer in combining single cell techniques, genome-editing, and systems biology to explore the cancer field’s most pressing problems.
Including BRCA1 testing with prenatal carrier screening could identify people at risk of breast, ovarian, and pancreatic cancer at a time when cancer screening could save their lives.
A study from Columbia researchers suggests that changing a single letter in the DNA code of selected genes in T cells may supercharge cell therapies against cancer.
Cancer centers announce the establishment of a research consortium focused on accelerating the discovery and development of novel cancer therapeutics and diagnostics for the benefit of patients.
An experimental urine test that detects genetic changes associated with prostate cancer identified 92 percent of men with elevated PSA levels who had more aggressive disease.
A Super Bowl ad has launched a new campaign at NewYork-Presbyterian Hospital that showcases Columbia and Weill Cornell expertise in cancer, particularly immunotherapy.
A comprehensive analysis of the molecular characteristics of gliomas—the most common malignant brain tumor—explains why some patients diagnosed with slow-growing (low-grade) tumors quickly succumb to the disease while others with more aggressive (high-grade) tumors survive for many years.
NewYork-Presbyterian, Columbia University Medical Center and Weill Cornell Medicine are among the nation’s top cancer centers calling for increased human papillomavirus (HPV) vaccination for the prevention of cancer.
Researchers have identified a biomarker that predicts which stage II colon cancer patients may benefit from adjuvant chemotherapy to prevent a disease recurrence.